Management of uterine leiomyosarcoma in Australia

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 39, Issue 1, 1999, Pages 93-98

  Gard, Gregory B ^a,b   Mulvany, Nicholas J ^a   Quinn, Michael A ^c  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IFOSFAMIDE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; AGED; ARTICLE; AUSTRALIA; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GYNECOLOGY; HUMAN; LEIOMYOSARCOMA; ONCOLOGY; OVARIECTOMY; PATHOLOGY; PATIENT CARE; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; PREMENOPAUSE; PRIORITY JOURNAL; RADIOTHERAPY; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE; UTERUS CANCER;

EID: 0033046616     PISSN: 00048666     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1479-828x.1999.tb03453.x     Document Type: Article

References (17)

1. Olah KS, Dunn JA, Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynaecol 1992; 99: 590-594.
2. O'Leary TJ, Steffes MW. Can You Count on the Mitotic Index? Hum Pathol 1996; 27: 147-151.
3. Bell SW, Kempson RL, Hendrickson MR. Problematic Uterine Smooth Muscle Neoplasms. Clinicopathologic Study of 213 Cases. Am J Surg Pathol 1994; 18: 535-558.
4. Major FJ, Blessing JA, Silverberg SG et al. Prognostic Factors in Early-Stage Uterine Sarcoma - A Gynecologic Oncology Group Study. Cancer 1993; 71: 1702-1709.
5. Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL. Treatment of Uterine Leiomyosarcoma. Obstet Gynecol 1988; 71: 845-850.
6. Goff BA, Rice LW, Fleischhacker D et al. Uterine Leiomyosarcoma and Endometrial Stromal Sarcoma Lymph Node Metastases and Sites of Recurrence. Gynecol Oncol 1993; 50: 105-109.
7. Rose PG, Piver MS, Tsukada Y, Lau T. Patterns of metastasis in uterine sarcoma: An autopsy study. Cancer 1989; 63: 935-938.
8. Omura GA, Blessing JA, Major FJ et al. A Randomized Clinical Trial of Adjuvant Adriamycin in Uterine Sarcomas: A Gynecologic Oncology Group Study. J Clin Oncol 1985; 3 1240-1245.
9. Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage 1 and 2 uterine sarcoma. Int J Radiat Oncol Biol Phys 1986; 12: 2127-2130.
10. Hempling RE, Piver MS, Baker TR. Impact on Progression-Free Survival of Adjuvant Cyclophosphamide, Vincristine, Doxorubicin (Adriamycin) and Dacarbazine (CYVADIC) Chemotherapy for Stage 1 Uterine Sarcoma. Am J Clin Oncol 1995; 18: 282-286.
11. Omura GA, Major FJ, Blessing JA et al. A Randomized Study of Adriamycin With and Without Dimethyl Triazenoimidazole Carboxamide in Advanced Uterine Sarcomas. Cancer 1983; 52: 626-632.
12. Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase 2 trial of ifosfamide and mesna in leiomyosarcoma of the uterus: A Gynecologic Oncology Group Study. Am J Obstet Gynecol 1992; 16: 556-559.
13. Sutton GP, Blessing JA, Malfetano JH. Ifosfamide and Doxorubicin in the Treatment of Advanced Leiomyosarcomas of the Uterus: A Gynecologic Oncology Group Study. Gynecol Oncol 1996; 62: 226-229.
14. Aaro LA, Symmonds RE, Dockerty MB. Sarcoma of the uterus: A clinical and pathologic study of 177 cases. Am J Obstet Gynecol 1966; 94: 101-109.
15. Barter JF, Smith EB, Szpak CA, Hinshaw W, Clarke-Pearson DL, Creasman WT. Leiomyosarcoma of the uterus: Clinicopathologic study of 21 cases. Gynecol Oncol 1985; 21: 220-232.
16. Chen SS. Propensity of Retroperitoneal Lymph Node Metastasis in Patients with Stage 1 Sarcoma of the Uterus. Gynecol Oncol 1989; 32: 215-217.
17. Echt G, Jepson J, Steel J et al. Treatment of Uterine Sarcomas. Cancer 1990; 66: 35-39.